Table 1

Patient demographic data and baseline characteristics (intention-to-treat population)

CZP 400 mg (n=89)
Age, mean±SD, years30.2±9.9
BMI, mean±SD, kg/m2 22.1±3.6
Males, n (%)30 (34)
CDEIS
 Mean±SD14.5±5.3
 Median13.3
 IQR10.3–16.9
CDAI
 Mean±SD297±75
 Median290
 IQR236–342
CRP, mg/l
 Geometric mean (CV)19 (1.4)
 Median29
 IQR9–46
Disease duration, years
 Mean±SD7.9±7.9
 Median6.5
Number of resections, n (%)
 071 (80)
 111 (12)
 25 (6)
 32 (2)
Prior anti-TNF therapy, n (%)2 (2)
At least one concomitant medication potentially influencing CD, % patients79
 Immunosuppressants51
 Corticosteroids42
 5-Aminosalicylic acid22
 Antibiotics15
  • BMI, body mass index; CD, Chron's disease; CDAI, Crohn's Disease Activity Index; CDEIS, Crohn's Disease Endoscopic Index of Severity; CRP, C reactive protein; CV, coefficient of variation; CZP, certolizumab pegol; TNF, tumour necrosis factor.